Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity.
Meeus F, Funeh CN, Awad RM, Zeven K, Autaers D, De Becker A, Van Riet I, Goyvaerts C, Tuyaerts S, Neyns B, Devoogdt N, De Vlaeminck Y, Breckpot K. Meeus F, et al. Among authors: tuyaerts s. J Immunother Cancer. 2024 Nov 19;12(11):e009110. doi: 10.1136/jitc-2024-009110. J Immunother Cancer. 2024. PMID: 39562005
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
De Jaeghere EA, Hamerlinck H, Tuyaerts S, Lippens L, Van Nuffel AMT, Baiden-Amissah R, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Verhasselt B, Denys HG. De Jaeghere EA, et al. Among authors: tuyaerts s. Gynecol Oncol. 2024 Nov 7;191:275-286. doi: 10.1016/j.ygyno.2024.10.020. Online ahead of print. Gynecol Oncol. 2024. PMID: 39515198
Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma.
Duerinck J, Lescrauwaet L, Dirven I, Del'haye J, Stevens L, Geeraerts X, Vaeyens F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M, Lebrun L, Salmon I, Kockx M, Tuyaerts S, Neyns B. Duerinck J, et al. Among authors: tuyaerts s. Neuro Oncol. 2024 Oct 16:noae177. doi: 10.1093/neuonc/noae177. Online ahead of print. Neuro Oncol. 2024. PMID: 39406392
A randomized phase II clinical trial of stereotactic body radiation therapy (SBRT) and systemic pembrolizumab with or without intratumoral avelumab/ipilimumab plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells in solid tumors.
Vounckx M, Tijtgat J, Stevens L, Dirven I, Ilsen B, Vandenbroucke F, Raeymaeckers S, Vekens K, Forsyth R, Geeraerts X, Van Riet I, Schwarze JK, Tuyaerts S, Decoster L, De Ridder M, Dufait I, Neyns B. Vounckx M, et al. Among authors: tuyaerts s. Cancer Immunol Immunother. 2024 Jul 2;73(9):167. doi: 10.1007/s00262-024-03751-0. Cancer Immunol Immunother. 2024. PMID: 38954010 Free PMC article. Clinical Trial.
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Trozzi R, Tuyaerts S, Annibali D, Herreros Pomares A, Boog L, Van Dam P, Leunen K, Deroose C, Trum H, Amant F. Trozzi R, et al. Among authors: tuyaerts s. Int J Gynecol Cancer. 2024 Aug 5;34(8):1217-1224. doi: 10.1136/ijgc-2023-005229. Int J Gynecol Cancer. 2024. PMID: 38724237 Clinical Trial.
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade.
De Wispelaere W, Annibali D, Tuyaerts S, Messiaen J, Antoranz A, Shankar G, Dubroja N, Herreros-Pomares A, Baiden-Amissah REM, Orban MP, Delfini M, Berardi E, Van Brussel T, Schepers R, Philips G, Boeckx B, Baietti MF, Congedo L, HoWangYin KY, Bayon E, Van Rompuy AS, Leucci E, Tabruyn SP, Bosisio F, Mazzone M, Lambrechts D, Amant F. De Wispelaere W, et al. Among authors: tuyaerts s. Clin Transl Med. 2024 May;14(5):e1655. doi: 10.1002/ctm2.1655. Clin Transl Med. 2024. PMID: 38711203 Free PMC article.
Intratumoral administration of the immunologic adjuvant AS01B in combination with autologous CD1c (BDCA-1)+/CD141 (BDCA-3)+ myeloid dendritic cells plus ipilimumab and intravenous nivolumab in patients with refractory advanced melanoma.
Tijtgat J, Geeraerts X, Boisson A, Stevens L, Vounckx M, Dirven I, Schwarze JK, Raeymaeckers S, Forsyth R, Van Riet I, Tuyaerts S, Willard-Gallo K, Neyns B. Tijtgat J, et al. Among authors: tuyaerts s. J Immunother Cancer. 2024 Jan 11;12(1):e008148. doi: 10.1136/jitc-2023-008148. J Immunother Cancer. 2024. PMID: 38212127 Free PMC article.
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.
Schwarze JK, Tijtgat J, Awada G, Cras L, Vasaturo A, Bagnall C, Forsyth R, Dufait I, Tuyaerts S, Van Riet I, Neyns B. Schwarze JK, et al. Among authors: tuyaerts s. J Immunother Cancer. 2022 Sep;10(9):e005141. doi: 10.1136/jitc-2022-005141. J Immunother Cancer. 2022. PMID: 36113895 Free PMC article. Clinical Trial.
56 results